What most investors miss
Trends, drivers and alerts — the full picture.
Not enough data yet
Not enough valuation history to place this in context.
Not enough data yet
Not enough revenue history to measure growth.
Fair value
Trading about 10% below our fair-value range
✦ The read
Certara, Inc.'s earnings-quality signal is not available yet.
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine DemandGlobeNewswire Inc.·
The Market Just Told You Which Layer Of AI Biology It Is Paying ForGlobeNewswire Inc.·
[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)GlobeNewswire Inc.·
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the FirmGlobeNewswire Inc.·
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire Inc.·
